Breaking News, Trials & Filings

FDA Approves AstraZeneca & Daiichi Sankyo’s Datroway for Metastatic Breast Cancer

The approval was based on results from the TROPION-Breast01 Phase III trial.

Author Image

By: Charlie Sternberg

Associate Editor

AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan or Dato-DXd) has been approved by the FDA in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. Datroway is a specifically engineered TROP2-directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters